N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydron;chloride (BioDeep_00001054200)
代谢物信息卡片
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydron;chloride
化学式: C19H28ClN5O4 (425.1829718000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: [H+].CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.[Cl-]
InChI: 1H
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mina Wadie, Hoda M Marzouk, Mamdouh R Rezk, Ezzat M Abdel-Moety, Mahmoud A Tantawy. A sensing platform of molecular imprinted polymer-based polyaniline/carbon paste electrodes for simultaneous potentiometric determination of alfuzosin and solifenacin in binary co-formulation and spiked plasma.
Analytica chimica acta.
2022 Apr; 1200(?):339599. doi:
10.1016/j.aca.2022.339599. [PMID: 35256148] - Heba Samir Elama, Shereen M Shalan, Yasser El-Shabrawy, Manal I Eid, Abdallah M Zeid. Utilization of a micellar matrix for simultaneous spectrofluorimetric estimation of alfuzosin hydrochloride and vardenafil hydrochloride.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2022 Feb; 266(?):120420. doi:
10.1016/j.saa.2021.120420. [PMID: 34619505] - Monica Mazzarino, Cristian Camuto, Fabio Comunità, Xavier de la Torre, Carlotta Stacchini, Francesco Botrè. Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 Nov; 1185(?):122989. doi:
10.1016/j.jchromb.2021.122989. [PMID: 34678705] - Thuy Doan Minh, Tuan Nguyen Thanh Ha, Thuan Nguyen Duy, Ngan Nguyen Hoang, Dung PhamTien, Hung Pham Thai, Hoa Nguyen Thi, Phuong Dang Thi Lan, Binh Pham Quoc, D Y Ivkin, M N Povydysh, Bang Nguyen Cong, M V Krasnova. Linh Phu Khang Tue Tinh inhibited prostate proliferation in rats induced benign prostatic hyperplasia by testosterone propionate.
Journal of ethnopharmacology.
2021 Oct; 279(?):114388. doi:
10.1016/j.jep.2021.114388. [PMID: 34224813] - Makinna C Oestreich, Robin Wm Vernooij, Niranjan J Sathianathen, Eu Chang Hwang, Gretchen M Kuntz, Alex Koziarz, Charles D Scales, Philipp Dahm. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults.
The Cochrane database of systematic reviews.
2020 11; 11(?):CD013393. doi:
10.1002/14651858.cd013393.pub2. [PMID: 33179245] - Abdel Qader Al Bawab, Bashar A Alkhalidi, Esra'a Albarahmieh, Sami M A Qassim, Mohammad A D Al-Saifi, Bashar Al-Saifi, Jonathan Ling, Walid Al-Qerem. Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended-Release Tablets.
Clinical pharmacology in drug development.
2020 10; 9(7):780-784. doi:
10.1002/cpdd.860. [PMID: 32770667] - Gokhan Sonmez, Ulas Serkan Topaloglu, Murat Keske, Abdullah Demirtas. Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome?.
Urology journal.
2020 08; 17(5):517-521. doi:
10.22037/uj.v16i7.6204. [PMID: 32869259] - Markos Karavitakis, Iason Kyriazis, Muhammad Imran Omar, Stavros Gravas, Jean-Nicolas Cornu, Marcus J Drake, Mauro Gacci, Christian Gratzke, Thomas R W Herrmann, Stephan Madersbacher, Malte Rieken, Mark J Speakman, Kari A O Tikkinen, Yuhong Yuan, Charalampos Mamoulakis. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis.
European urology.
2019 05; 75(5):788-798. doi:
10.1016/j.eururo.2019.01.046. [PMID: 30773327] - M I Walash, F Belal, M Fathy, S Zayed, H Borg. Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection.
Annales pharmaceutiques francaises.
2019 Jan; 77(1):28-37. doi:
10.1016/j.pharma.2018.08.003. [PMID: 30172351] - Mahmoud A Omar, Mohamed A Hammad, Baher I Salman. Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α1 -blocker drugs: Application in pharmaceutical preparations and human plasma.
Luminescence : the journal of biological and chemical luminescence.
2018 Nov; 33(7):1226-1234. doi:
10.1002/bio.3539. [PMID: 30094938] - Ling Gong, Yanyan Sun, Miao Yu, Ying Gao, Meijuan Zou, Gang Cheng. Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release.
AAPS PharmSciTech.
2018 Oct; 19(7):3277-3286. doi:
10.1208/s12249-018-1168-z. [PMID: 30215168] - Mahmoud A Omar, Abdel-Maaboud I Mohamed, Sayed M Derayea, Mohamed A Hammad, Abobakr A Mohamed. An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2018 Apr; 195(?):215-222. doi:
10.1016/j.saa.2018.01.077. [PMID: 29414581] - Mohamed A Hammad, Mahmoud A Omar, Baher I Salman. Utility of Hantzsch reaction for development of highly sensitive spectrofluorimetric method for determination of alfuzosin and terazosin in bulk, dosage forms and human plasma.
Luminescence : the journal of biological and chemical luminescence.
2017 Sep; 32(6):1066-1071. doi:
10.1002/bio.3292. [PMID: 28303653] - Faik Kose, Zafer Turkyilmaz, Kaan Sonmez, Ramazan Karabulut, Aylar Poyraz, Ozlem Gulbahar, Arzu Aral, Cagri Damar, Cem Kaya, Abdullah Can Basaklar. The effect of alfuzosin on renal resistive index, urinary electrolytes and β2 microglobulin levels and TGF β-1 levels of kidney tissue in rats with unilateral ureteropelvic junction obstruction.
Renal failure.
2016 Sep; 38(8):1283-90. doi:
10.1080/0886022x.2016.1207049. [PMID: 27402370] - Shucheng Liu, Ying Yu, Yang Gao, Xiong Yang, Zili Pang. Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.
Urolithiasis.
2016 Apr; 44(2):185-90. doi:
10.1007/s00240-015-0810-4. [PMID: 26242466] - Blayne Welk, Eric McArthur, Lisa-Ann Fraser, Jade Hayward, Stephanie Dixon, Y Joseph Hwang, Michael Ordon. The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study.
BMJ (Clinical research ed.).
2015 Oct; 351(?):h5398. doi:
10.1136/bmj.h5398. [PMID: 26502947] - Nannan Gao, Hao Wu, Yafen Chang, Xiaozhen Guo, Lizhen Zhang, Liming Du, Yunlong Fu. Mixed micelle cloud point-magnetic dispersive μ-solid phase extraction of doxazosin and alfuzosin.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2015 Jan; 134(?):10-6. doi:
10.1016/j.saa.2014.06.095. [PMID: 24995413] - Suleyman Bulut, Cuneyt Ozden, Binhan Kagan Aktas, Tagmac Deren, Suleyman Tagci, Cevdet Serkan Gokkaya, Mehmet Murat Baykam, Ali Memis. Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
Urologia internationalis.
2015; 94(2):181-6. doi:
10.1159/000363581. [PMID: 25139617] - Miguel Maldonado-Ávila, Hugo A Manzanilla-García, José A Sierra-Ramírez, José D Carrillo-Ruiz, Juan C González-Valle, Emanuelle Rosas-Nava, José Guzman-Esquivel, Isaac R Labra-Salgado. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
International urology and nephrology.
2014 Apr; 46(4):687-90. doi:
10.1007/s11255-013-0515-y. [PMID: 24061764] - Mehmet Umul, Ahmet Bariş Altay, Fikret Bademkiran, Burak Turna, Mehmet Bülent Semerci, Erdal Apaydin, Necmettin Cikili. The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity.
Turkish journal of medical sciences.
2014; 44(4):681-6. doi:
10.3906/sag-1304-122. [PMID: 25551942] - Shabana Nazarudheen, Surajit Dey, Kirti Kandhwal, Rachna Arora, Simrit Reyar, Arshad H Khuroo, Tausif Monif, Sumit Madan, Vinod Arora. Combining benefits of an adrenergic and a muscarinic blocker in a single formulation - a pharmacokinetic evaluation.
Regulatory toxicology and pharmacology : RTP.
2013 Nov; 67(2):226-31. doi:
10.1016/j.yrtph.2013.07.015. [PMID: 23933032] - J H Chung, J Y Lee, D H Kang, J K Jo, J W Lee, S H Lee, K S Lee, T H Kim, J H Han, S W Lee. Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.
International journal of clinical practice.
2013 Sep; 67(9):870-5. doi:
10.1111/ijcp.12108. [PMID: 23952466] - Teemu J Murtola, Paula M Kujala, Teuvo L J Tammela. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
The Prostate.
2013 Jun; 73(9):923-31. doi:
10.1002/pros.22638. [PMID: 23334943] - Ping Liang, Feng Lan, Andrew S Lee, Tingyu Gong, Veronica Sanchez-Freire, Yongming Wang, Sebastian Diecke, Karim Sallam, Joshua W Knowles, Paul J Wang, Patricia K Nguyen, Donald M Bers, Robert C Robbins, Joseph C Wu. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Circulation.
2013 Apr; 127(16):1677-91. doi:
10.1161/circulationaha.113.001883. [PMID: 23519760] - M V Razdorskaia, A I Neĭmark, R T Aliev. [Modern approaches to the treatment of patients with overactive bladder and urge urinary incontinence].
Urologiia (Moscow, Russia : 1999).
2013 Jan; ?(1):44-6, 48. doi:
NULL. [PMID: 23662495] - M İ Öztürk, S Kalkan, O Koca, M Güneş, M Akyüz, M I Karaman. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Andrologia.
2012 May; 44 Suppl 1(?):791-5. doi:
10.1111/j.1439-0272.2011.01268.x. [PMID: 22211956] - Xenophon K Giannakopoulos, Christos Giotis, Spyridon Ch Karkabounas, Ioannis I Verginadis, Yannis V Simos, Dimitrios Peschos, Angelos M Evangelou. Effects of pulsed electromagnetic fields on benign prostate hyperplasia.
International urology and nephrology.
2011 Dec; 43(4):955-60. doi:
10.1007/s11255-011-9944-7. [PMID: 21537858] - Lysander Hin Chau, Dominic Chi Kin Tai, Berry Tat Chow Fung, James Cheuk Man Li, Chi Wai Fan, Michael Ka Wah Li. Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial.
International journal of urology : official journal of the Japanese Urological Association.
2011 Jul; 18(7):510-4. doi:
10.1111/j.1442-2042.2011.02780.x. [PMID: 21592234] - Abdul Jabbar Pirzada, Adeel Anwar, Atif Javed, Imran Memon, Ariz Mohammad. Role of alpha-1 blocker in expulsion of stone fragments after extracorporeal shock wave lithotripsy for renal stones.
Journal of Ayub Medical College, Abbottabad : JAMC.
2011 Apr; 23(2):125-9. doi:
NULL. [PMID: 24800362] - R Delgado Alvira, E Calleja Aguayo, M A Rihuete Heras, M Ruiz de Temiño Bravo, J Gracia Romero. [Our experience with the use of alpha-lithic therapy in the treatment of voiding dysfunction].
Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica.
2010 Oct; 23(4):197-200. doi:
NULL. [PMID: 21520549] - Daniel A Shoskes, J Curtis Nickel, Michael W Kattan. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT.
Urology.
2010 Jun; 75(6):1249-53. doi:
10.1016/j.urology.2010.01.021. [PMID: 20363491] - Richard Beddingfield, Renato N Pedro, Bryan Hinck, Carly Kreidberg, Kendall Feia, Manoj Monga. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study.
The Journal of urology.
2009 Jan; 181(1):170-6. doi:
10.1016/j.juro.2008.09.026. [PMID: 19013590] - Hiren N Mistri, Arvind G Jangid, Ashutosh Pudage, Dhiraj M Rathod, Pranav S Shrivastav. Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2008 Dec; 876(2):236-44. doi:
10.1016/j.jchromb.2008.10.050. [PMID: 19010093] - F Hugon-Chapuis, J U Mullot, G Tuffal, M-C Hennion, V Pichon. Selective and automated sample pretreatment by molecularly imprinted polymer for the analysis of the basic drug alfuzosin from plasma.
Journal of chromatography. A.
2008 Jul; 1196-1197(?):73-80. doi:
10.1016/j.chroma.2008.04.038. [PMID: 18466912] - J Curtis Nickel. Role of alpha1-blockers in chronic prostatitis syndromes.
BJU international.
2008 Mar; 101 Suppl 3(?):11-6. doi:
10.1111/j.1464-410x.2008.07496.x. [PMID: 18307680] - Stefano Palea, David F Chang, Moez Rekik, Alain Regnier, Philippe Lluel. Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles: possible model for intraoperative floppy-iris syndrome.
Journal of cataract and refractive surgery.
2008 Mar; 34(3):489-96. doi:
10.1016/j.jcrs.2007.10.045. [PMID: 18299077] - A S Fayed, M A Shehata, N Y Hassan, S A Weshahy. Stability-indicating spectrophotometric and spectrofluorimetric methods for determination of alfuzosin hydrochloride in the presence of its degradation products.
Die Pharmazie.
2007 Nov; 62(11):830-5. doi:
NULL. [PMID: 18065098] - A M Miller. [The experience in postoperative administration of alpha-adrenoblockers].
Urologiia (Moscow, Russia : 1999).
2007 Sep; ?(5):55-8. doi:
NULL. [PMID: 18254227] - Vinod K Gupta, Ashok K Singh, Barkha Gupta. Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum.
Combinatorial chemistry & high throughput screening.
2007 Aug; 10(7):560-70. doi:
10.2174/138620707782152416. [PMID: 17979639] - Steven A Kaplan, Ricardo R Gonzalez, Alexis E Te. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
European urology.
2007 Jun; 51(6):1717-23. doi:
10.1016/j.eururo.2007.01.033. [PMID: 17258855] - Vittorio Magri, Alberto Trinchieri, Emanuele Montanari, Alberto Del Nero, Barbara Mangiarotti, Pasquale Zirpoli, Magda de Eguileor, Emanuela Marras, Isabella Ceriani, Anne Vral, Gianpaolo Perletti. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
2007 Jun; 79(2):84-92. doi:
NULL. [PMID: 17695414] - Florence Chapuis, Jean-Ulrich Mullot, Valérie Pichon, Gilles Tuffal, Marie-Claire Hennion. Molecularly imprinted polymers for the clean-up of a basic drug from environmental and biological samples.
Journal of chromatography. A.
2006 Dec; 1135(2):127-34. doi:
10.1016/j.chroma.2006.09.076. [PMID: 17055520] - Wayne J G Hellstrom, Suresh C Sikka. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers.
The Journal of urology.
2006 Oct; 176(4 Pt 1):1529-33. doi:
10.1016/j.juro.2006.06.004. [PMID: 16952675] - Claus G Roehrborn. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
BJU international.
2006 Apr; 97(4):734-41. doi:
10.1111/j.1464-410x.2006.06110.x. [PMID: 16536764] - Mark Emberton. Definition of at-risk patients: dynamic variables.
BJU international.
2006 Apr; 97 Suppl 2(?):12-5; discussion 21. doi:
10.1111/j.1464-410x.2006.06099.x. [PMID: 16507047] - Tulga Egilmez, Mir Ali Pourbagher, Sezgin Guvel, Ferhat Kilinc, Tahsin Turunc, Hakan Ozkardes. Effects of selective alpha-1-adrenergic receptor blockers on bladder weight.
Urologia internationalis.
2006; 76(1):42-50. doi:
10.1159/000089734. [PMID: 16401920] - Kevin T McVary. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
The Journal of urology.
2006 Jan; 175(1):35-42. doi:
10.1016/s0022-5347(05)00032-7. [PMID: 16406865] - V V Danilov, I Iu Vol'nykh, T I Danilova, S K Abdulaleva. [The role of alpha1-adrenoblocker alfuzosine in diagnostic-therapeutic algorithm of hyperactive urinary bladder management in women and selection of patients for treatment with M-cholinergic antagonists].
Urologiia (Moscow, Russia : 1999).
2005 Jan; ?(1):44-7. doi:
NULL. [PMID: 15776831] - S A McNeill, T B Hargreave, Claus G Roehrborn. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Urology.
2005 Jan; 65(1):83-9; discussion 89. doi:
10.1016/j.urology.2004.07.042. [PMID: 15667868] - S A McNeill, T B Hargreave. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
The Journal of urology.
2004 Jun; 171(6 Pt 1):2316-20. doi:
10.1097/01.ju.0000127743.80759.7a. [PMID: 15126812] - T M de Reijke, P Klarskov. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
BJU international.
2004 Apr; 93(6):757-62. doi:
10.1111/j.1464-410x.2003.04720.x. [PMID: 15049986] - David R P Guay. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
The American journal of geriatric pharmacotherapy.
2004 Mar; 2(1):14-23. doi:
10.1016/s1543-5946(04)90003-7. [PMID: 15555475] - Murat Bozlu, Ercüment Ulusoy, Selahittin Cayan, Esen Akbay, Sadik Görür, Erdem Akbay. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Scandinavian journal of urology and nephrology.
2004; 38(5):391-5. doi:
10.1080/00365590410015678. [PMID: 15764250] - Mary Lee. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2003 Jul; 60(14):1426-39. doi:
10.1093/ajhp/60.14.1426. [PMID: 12892027] - J L Wiesner, F C W Sutherland, G H van Essen, H K L Hundt, K J Swart, A F Hundt. Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2003 May; 788(2):361-8. doi:
10.1016/s1570-0232(03)00064-3. [PMID: 12705976] - C De Nunzio, G Franco, F Iori, C Leonardo, V Minardi, C Laurenti. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
Urologia internationalis.
2003; 71(1):31-6. doi:
10.1159/000071090. [PMID: 12845257] - Thomas C Marbury, Robert A Blum, Clémence Rauch, Jean-Louis Pinquier. Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.
Journal of clinical pharmacology.
2002 Dec; 42(12):1311-7. doi:
10.1177/0091270002239360. [PMID: 12463725] - P Ahtoy, P Chrétien, T Dupain, C Rauch, A Rouchouse, A Delfolie. Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
International journal of clinical pharmacology and therapeutics.
2002 Jul; 40(7):289-94. doi:
10.5414/cpp40289. [PMID: 12139205] - Jean J M C H de la Rosette, Barbara B M Kortmann, Cristina Rossi, Gabe S Sonke, Diamandis L Floratos, Lambertus A L M Kiemeney. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
The Journal of urology.
2002 Apr; 167(4):1734-9. doi:
10.1097/00005392-200204000-00035. [PMID: 11912399] - Klaus Höfner, Udo Jonas. Alfuzosin: a clinically uroselective alpha1-blocker.
World journal of urology.
2002 Apr; 19(6):405-12. doi:
NULL. [PMID: 12022709] - P van Kerrebroec, A Jardin, P van Cangh, K U Laval. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
European urology.
2002 Jan; 41(1):54-60; discussion 60. doi:
10.1016/s0302-2838(01)00016-1. [PMID: 11999466] - Kate McKeage, Greg L Plosker. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
Drugs.
2002; 62(4):633-53. doi:
10.2165/00003495-200262040-00009. [PMID: 11893233] - S A McNeill, T B Hargreave, C Geffriaud-Ricouard, J Santoni, C G Roehrborn. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
Urology.
2001 Mar; 57(3):459-65. doi:
10.1016/s0090-4295(00)01021-9. [PMID: 11248620] - S A McNeill. Does acute urinary retention respond to alpha-blockers alone?.
European urology.
2001 Mar; 39 Suppl 6(?):7-12. doi:
10.1159/000052593. [PMID: 11306895] - O B Loran, P I Rasner, D Kosko, D Iu Pushkar'. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
Urologiia (Moscow, Russia : 1999).
2001 Jan; ?(1):8-10. doi:
NULL. [PMID: 11233234] - M M Başar, A Atan, O Ozergin, M Yildiz. The efficacy of alfuzosin treatment in patients with prostatism.
International urology and nephrology.
2001; 33(3):493-7. doi:
10.1023/a:1019555020671. [PMID: 12230279] - NULL. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
European urology.
2000 Jun; 37(6):680-6. doi:
10.1159/000020218. [PMID: 10828668] - P van Kerrebroeck, A Jardin, K U Laval, P van Cangh. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
European urology.
2000 Mar; 37(3):306-13. doi:
10.1159/000052361. [PMID: 10720857] - V N Tkachuk, I V Kuz'min. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
Urologiia i nefrologiia.
1998 Mar; ?(2):38-40. doi:
NULL. [PMID: 9577703] - D J Martin, P Lluel, T Pouyet, C Rauch-Desanti, I Angel. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations.
Life sciences.
1998; 63(3):169-76. doi:
10.1016/s0024-3205(98)00257-4. [PMID: 9698046] - M D'Armiento, R Damiano, M De Sio, S Perdonà, C Santonastaso, D Mattace Raso. [Role of alfuzosin in the treatment of functional voiding disorders in women].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
1997 Feb; 69 Suppl 1(?):43-5. doi:
. [PMID: 9181922] - E B Mazo, I A Matushevskiĭ, Iu Iu Nikitin. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
Terapevticheskii arkhiv.
1997; 69(10):79-82. doi:
NULL. [PMID: 9471799] - J M Buzelin, S Roth, C Geffriaud-Ricouard, M C Delauche-Cavallier. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
European urology.
1997; 31(2):190-8. doi:
10.1159/000474449. [PMID: 9076465] - A Jardin, H Bensadoun, M C Delauche-Cavallier, P Attali. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
British journal of urology.
1993 Nov; 72(5 Pt 1):615-20. doi:
10.1111/j.1464-410x.1993.tb16220.x. [PMID: 10071548] - P Salva, G Bianchetti, P Morselli, G Garcia-Teresa, J Costa. Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses.
Biopharmaceutics & drug disposition.
1992 Nov; 13(8):583-90. doi:
10.1002/bdd.2510130804. [PMID: 1358243] - A Jardin, H Bensadoun, M C Delauche-Cavallier, P Attali. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Lancet (London, England).
1991 Jun; 337(8755):1457-61. doi:
10.1016/0140-6736(91)93140-5. [PMID: 1710750] - G Leposavic, M R Dashwood, J Ginsburg, J C Buckingham. Peripubertal changes in the nature of the GnRH response to alpha-adrenoceptor stimulation in vitro and their modulation by testosterone.
Neuroendocrinology.
1990 Jul; 52(1):82-9. doi:
10.1159/000125543. [PMID: 1975657] - A Rouchouse, M Manoha, A Durand, J P Thenot. Direct high-performance liquid chromatographic determination of the enantiomers of alfuzosin in plasma on a second-generation alpha 1-acid glycoprotein chiral stationary phase.
Journal of chromatography.
1990 May; 506(?):601-10. doi:
10.1016/s0021-9673(01)91608-5. [PMID: 2376608] - P Cramer, E Neveux, F Régnier, J Depassio, E Bérard. Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin.
Paraplegia.
1989 Apr; 27(2):119-24. doi:
10.1038/sc.1989.18. [PMID: 2566147] - A M Krstulovic, J L Vende. Improved performance of the second generation alpha 1-AGP columns: applications to the routine assay of plasma levels of alfuzosin hydrochloride.
Chirality.
1989; 1(3):243-5. doi:
10.1002/chir.530010311. [PMID: 2642053] - S Leto di Priolo, P Priore, G Cocco, C Sfrisi, J L Cazor. Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.
European journal of clinical pharmacology.
1988; 35(1):25-30. doi:
10.1007/bf00555503. [PMID: 2905990] - P Guinebault, M Broquaire, C Colafranceschi, J P Thénot. High-performance liquid chromatographic determination of alfuzosin in biological fluids with fluorimetric detection and large-volume injection.
Journal of chromatography.
1986 Feb; 353(?):361-9. doi:
10.1016/s0021-9673(01)87106-5. [PMID: 2871035]